Eli Lilly posts Q3 beat, lifts FY2026 revenue outlook and trims EPS guidance
Eli Lilly reported third‑quarter 2026 revenue of $24.4 billion, up 39% year‑over‑year, and GAAP EPS of $7.22, a 16% increase. The company raised its full‑year revenue guidance to $91.0‑$92.0 billion, while adjusting its full‑year non‑GAAP EPS outlook down to $35.00‑$36.00 per share because of $4.57 per share of acquired IPR&D charges linked to recent acquisitions. Strong sales of Mounjaro ($10.72 billion) and Zepbound ($5.35 billion) drove the results, while the new obesity pill Foundayo generated $184 million.




